JP2013544847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544847A5 JP2013544847A5 JP2013542202A JP2013542202A JP2013544847A5 JP 2013544847 A5 JP2013544847 A5 JP 2013544847A5 JP 2013542202 A JP2013542202 A JP 2013542202A JP 2013542202 A JP2013542202 A JP 2013542202A JP 2013544847 A5 JP2013544847 A5 JP 2013544847A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- hydrogen
- lymphoma
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- -1 5-chloropyridin-2-yl Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 108091005575 Bromodomain-containing proteins Proteins 0.000 claims 2
- 102000001805 Bromodomains Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 108091005625 BRD4 Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010008583 Chloroma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 201000005987 myeloid sarcoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 208000027500 optic nerve neoplasm Diseases 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000037964 urogenital cancer Diseases 0.000 claims 1
- 208000023747 urothelial carcinoma Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41911910P | 2010-12-02 | 2010-12-02 | |
| US61/419,119 | 2010-12-02 | ||
| US201161451332P | 2011-03-10 | 2011-03-10 | |
| US61/451,322 | 2011-03-10 | ||
| US201161482473P | 2011-05-04 | 2011-05-04 | |
| US61/482,473 | 2011-05-04 | ||
| US201161540788P | 2011-09-29 | 2011-09-29 | |
| US201161540725P | 2011-09-29 | 2011-09-29 | |
| US61/540,788 | 2011-09-29 | ||
| US61/540,725 | 2011-09-29 | ||
| PCT/US2011/063046 WO2012075383A2 (en) | 2010-12-02 | 2011-12-02 | Bromodomain inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544847A JP2013544847A (ja) | 2013-12-19 |
| JP2013544847A5 true JP2013544847A5 (enExample) | 2015-01-22 |
| JP5850944B2 JP5850944B2 (ja) | 2016-02-03 |
Family
ID=46235164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542202A Active JP5850944B2 (ja) | 2010-12-02 | 2011-12-02 | ブロモドメイン阻害剤およびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8796261B2 (enExample) |
| EP (1) | EP2646446B1 (enExample) |
| JP (1) | JP5850944B2 (enExample) |
| KR (1) | KR101871013B1 (enExample) |
| CN (1) | CN103415525B (enExample) |
| AR (1) | AR084070A1 (enExample) |
| AU (1) | AU2011336417B2 (enExample) |
| BR (1) | BR112013013167B1 (enExample) |
| CA (1) | CA2818187C (enExample) |
| CY (1) | CY1116578T1 (enExample) |
| DK (1) | DK2646446T3 (enExample) |
| EA (1) | EA022645B1 (enExample) |
| ES (1) | ES2545117T3 (enExample) |
| HR (1) | HRP20150858T1 (enExample) |
| HU (1) | HUE025321T2 (enExample) |
| IL (1) | IL226331A (enExample) |
| MX (1) | MX2013006214A (enExample) |
| NZ (1) | NZ611964A (enExample) |
| PL (1) | PL2646446T3 (enExample) |
| PT (1) | PT2646446E (enExample) |
| RS (1) | RS54175B1 (enExample) |
| SG (1) | SG190739A1 (enExample) |
| SI (1) | SI2646446T1 (enExample) |
| TW (1) | TWI572607B (enExample) |
| WO (1) | WO2012075383A2 (enExample) |
| ZA (1) | ZA201303776B (enExample) |
Families Citing this family (150)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
| KR101913109B1 (ko) | 2009-03-18 | 2018-10-31 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| US8981083B2 (en) | 2010-05-14 | 2015-03-17 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
| CA2799381A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| US8912221B2 (en) * | 2010-12-27 | 2014-12-16 | Hoffmann-La Roche Inc. | Biaryl amide derivatives |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| LT2773354T (lt) | 2011-11-01 | 2019-08-12 | Resverlogix Corp. | Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos |
| RU2666530C2 (ru) | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
| US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| AU2012382373A1 (en) * | 2012-06-12 | 2014-12-11 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
| CA2881996A1 (en) * | 2012-08-16 | 2014-02-20 | Bayer Pharma Aktiengesellschaft | 2,3-benzodiazepines |
| EP2900672B1 (de) | 2012-09-28 | 2017-02-22 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 5-aryl-triazolo-azepine |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| WO2014096965A2 (en) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| EP2958909A1 (de) * | 2013-02-19 | 2015-12-30 | Bayer Pharma Aktiengesellschaft | Bicyclo- und spirocyclisch substituierte 2,3-benzodiazepine |
| HK1212345A1 (en) | 2013-02-22 | 2016-06-10 | Bayer Pharma Aktiengesellschaft | 4-substituted pyrrolo- and pyrazolo-diazepines |
| CN105189514A (zh) | 2013-02-22 | 2015-12-23 | 拜耳医药股份有限公司 | 作为bet-蛋白抑制剂用于治疗过度增殖性疾病的吡咯并-和吡唑并-三唑并二氮杂卓 |
| WO2014134583A2 (en) * | 2013-02-28 | 2014-09-04 | Washington University | Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| MX2015012158A (es) * | 2013-03-11 | 2015-12-01 | Abbvie Inc | Inhibidores de bomodominio tetraciclicos fusionados. |
| WO2014139324A1 (en) * | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Tetracyclic bromodomain inhibitors |
| US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| CN105407894A (zh) | 2013-03-14 | 2016-03-16 | 康威基内有限公司 | 用于抑制含布罗莫结构域的蛋白质的方法和组合物 |
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| CA2901083A1 (en) | 2013-04-26 | 2014-10-30 | Beigene, Ltd. | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| US8975417B2 (en) * | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| ES2656471T3 (es) * | 2013-05-28 | 2018-02-27 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de BET y su uso en el tratamiento de enfermedades |
| CA2913741A1 (en) * | 2013-05-28 | 2014-12-04 | The Brigham And Women's Hospital, Inc. | Bet inhibition therapy for heart disease |
| SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
| WO2015004533A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| WO2015006193A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| WO2015015318A2 (en) | 2013-07-31 | 2015-02-05 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| KR20160036591A (ko) * | 2013-08-01 | 2016-04-04 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 함유하는 약학적 제제 |
| US20160158246A1 (en) * | 2013-08-06 | 2016-06-09 | Oncoethix Gmbh | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
| KR20160072261A (ko) * | 2013-11-08 | 2016-06-22 | 다나-파버 캔서 인스티튜트 인크. | 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법 |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| AU2014361381A1 (en) * | 2013-12-10 | 2016-06-16 | Abbvie Inc. | Bromodomain inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| KR20160111036A (ko) | 2014-01-31 | 2016-09-23 | 다나-파버 캔서 인스티튜트 인크. | 디아제판 유도체 및 그의 용도 |
| MX2016009974A (es) | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| WO2015121227A1 (de) * | 2014-02-14 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | 6,9-disubstituierte 1 -phenyl-3h-2,3-benzodiazepine und ihre verwendung als bromodomänen- inhibitoren |
| WO2015121268A1 (de) * | 2014-02-14 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | 1-phenyl-3h-2,3-benzodiazepine und ihre verwendung als bromodomänen-inhibitoren |
| JP2017071553A (ja) * | 2014-02-25 | 2017-04-13 | 味の素株式会社 | ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物 |
| RU2722179C2 (ru) | 2014-02-28 | 2020-05-28 | Тэнша Терапеутикс, Инк. | Лечение состояний, ассоциированных с гиперинсулинемией |
| US9580430B2 (en) | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| EP3125896A2 (en) * | 2014-04-04 | 2017-02-08 | Constellation Pharmaceuticals, Inc. | EXPRESSION LEVELS OF BCL-xL, BCL2, BCL-w, AND BAD AND CANCER THERAPIES |
| US9884874B2 (en) * | 2014-04-09 | 2018-02-06 | Kainos Medicine, Inc. | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| UA119870C2 (uk) | 2014-04-23 | 2019-08-27 | Інсайт Корпорейшн | 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET |
| EA033459B1 (ru) | 2014-05-29 | 2019-10-31 | Entasis Therapeutics Ltd | Конденсированные спироциклические гетероароматические соединения для лечения бактериальных инфекций |
| CA2952526A1 (en) * | 2014-06-18 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-protein inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino- or ether groups |
| CN106687463B (zh) * | 2014-06-20 | 2019-04-09 | 星座制药公司 | 一种乙酰胺类化合物的晶型 |
| WO2015195863A1 (en) | 2014-06-20 | 2015-12-23 | Constellation Pharmaceuticals, Inc. | Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
| MY187540A (en) * | 2014-08-01 | 2021-09-28 | Nuevolution As | Compounds active towards bromodomains |
| EP3177626A4 (en) | 2014-08-08 | 2017-12-27 | Dana Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| WO2016022970A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| EP3206749B1 (en) | 2014-10-14 | 2021-09-08 | The Regents of the University of California | The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation |
| UA122130C2 (uk) | 2014-10-27 | 2020-09-25 | Тенша Терапеутікс, Інк. | Інгібітори бромодомену |
| DK3212789T3 (da) * | 2014-10-31 | 2020-07-27 | Massachusetts Inst Technology | Massiv parallel kombinatorisk genetik til crispr |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| JP2017537946A (ja) | 2014-12-11 | 2017-12-21 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての置換複素環 |
| HK1245247A1 (zh) | 2014-12-17 | 2018-08-24 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| CN105985282B (zh) * | 2015-01-28 | 2020-12-08 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物及其应用 |
| WO2016138332A1 (en) | 2015-02-27 | 2016-09-01 | The Regents Of The University Of Michigan | 9h-pyrimido [4,5-b] indoles as bet bromodomain inhibitors |
| JP6903585B2 (ja) | 2015-03-13 | 2021-07-14 | レスバーロジックス コーポレイション | 補体関連疾患の治療のための組成物および治療方法 |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| ES2911886T3 (es) * | 2015-03-30 | 2022-05-23 | Jubilant Biosys Ltd | Derivados condensados tricíclicos de 1-(ciclo)alquilpiridin-2-ona útiles para el tratamiento del cáncer |
| CN111349118B (zh) | 2015-05-18 | 2023-08-22 | 住友制药肿瘤公司 | 具有增加的生物利用度的阿伏西地前药 |
| WO2016196065A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| AU2016283020A1 (en) | 2015-06-26 | 2018-01-04 | Tensha Therapeutics, Inc. | Treatment of nut midline carcinoma |
| JP2018526430A (ja) | 2015-07-10 | 2018-09-13 | アルヴィナス・インコーポレイテッド | タンパク質分解のｍｄｍ２系修飾因子および関連の使用方法 |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| WO2017037567A1 (en) * | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
| CA2997531A1 (en) * | 2015-09-09 | 2017-03-16 | Jubilant Biosys Limited | Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors |
| JP2018526424A (ja) | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用 |
| US11306105B2 (en) * | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| CR20180336A (es) | 2015-11-25 | 2018-08-06 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| ES2882066T3 (es) | 2016-02-15 | 2021-12-01 | Univ Michigan Regents | 1,4-oxazepinas fusionadas y análogos relacionados como inhibidores de bromodominio BET |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| AU2017246453A1 (en) | 2016-04-06 | 2018-11-08 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| CN113788818A (zh) | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| BR112018070859A2 (pt) | 2016-04-12 | 2019-02-05 | Univ Michigan Regents | degradantes da proteína de bet |
| DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
| DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
| AU2017281286B2 (en) | 2016-06-20 | 2021-05-20 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| US10975093B2 (en) | 2016-09-13 | 2021-04-13 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as BET protein degraders |
| CN110062759B (zh) | 2016-09-13 | 2022-05-24 | 密执安大学评议会 | 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬 |
| WO2018075908A1 (en) * | 2016-10-21 | 2018-04-26 | University Of Miami | Materials and methods for treating ophthalmic inflammation |
| AU2017367872B2 (en) | 2016-11-01 | 2022-03-31 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| EP3551633B1 (en) * | 2016-12-12 | 2021-03-31 | Leo Pharma A/S | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors |
| WO2018108231A1 (en) * | 2016-12-12 | 2018-06-21 | Leo Pharma A/S | Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors |
| WO2018111805A1 (en) * | 2016-12-13 | 2018-06-21 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
| JP2020506922A (ja) | 2017-01-31 | 2020-03-05 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物 |
| WO2018144789A1 (en) | 2017-02-03 | 2018-08-09 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
| JOP20190192A1 (ar) * | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
| WO2018207881A1 (ja) * | 2017-05-12 | 2018-11-15 | 武田薬品工業株式会社 | 複素環化合物 |
| ES3009020T3 (en) | 2017-05-31 | 2025-03-25 | Ayumi Pharmaceutical Corp | 6h-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| WO2019055444A1 (en) | 2017-09-13 | 2019-03-21 | The Regents Of The University Of Michigan | DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS |
| US11180510B2 (en) | 2017-11-06 | 2021-11-23 | Centre National De La Recherche Scientifique | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins |
| WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
| EP3819305A4 (en) | 2018-07-04 | 2022-04-06 | Mitsubishi Tanabe Pharma Corporation | AMIDE COMPOUND WITH BET PROTEOLYSIS-INDUCING ACTIVITY AND MEDICAL USE THEREOF |
| KR20210038921A (ko) | 2018-07-25 | 2021-04-08 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 브로모도메인 단백질 억제제로서의 설폭시민 화합물과 약학적 조성물 및 이의 의학적 용도 |
| EA202191489A1 (ru) | 2018-11-27 | 2021-09-10 | Констеллейшен Фармасьютикалс, Инк. | Способы лечения миелопролиферативных расстройств |
| WO2020112939A1 (en) | 2018-11-27 | 2020-06-04 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| WO2021091532A1 (en) | 2019-11-05 | 2021-05-14 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
| CN111518045A (zh) * | 2019-02-02 | 2020-08-11 | 博诺康源(北京)药业科技有限公司 | 一种具有苯并七元环结构的化合物、其制备方法及用途 |
| JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置 |
| WO2021091535A1 (en) | 2019-11-05 | 2021-05-14 | Constellation Pharmaceuticals, Inc. | Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor |
| WO2020257644A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| WO2020256739A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| CN112142711B (zh) * | 2019-06-28 | 2022-03-29 | 中国科学院上海药物研究所 | 取代噻吩类化合物、其制备方法及其用途 |
| CN114867727B (zh) | 2019-07-17 | 2025-02-21 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| CA3149095A1 (en) * | 2019-07-29 | 2021-02-04 | Constellation Pharmaceuticals, Inc. | Alpha-amino amide compounds for use in treating neurological disorders |
| PE20221582A1 (es) | 2019-12-19 | 2022-10-06 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de receptor de androgenos |
| CN115087658B (zh) | 2020-02-06 | 2025-02-28 | 田边三菱制药株式会社 | 具有诱导brd4蛋白质分解作用的磺酰胺或亚磺酰胺化合物及其药物用途 |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| KR20230026461A (ko) | 2020-06-23 | 2023-02-24 | 제넨테크, 인크. | 거대고리 화합물 및 이의 사용 방법 |
| KR20230048042A (ko) | 2020-08-04 | 2023-04-10 | 콘스텔레이션 파마슈티칼스, 인크. | 혈소판 증가증의 치료를 위한 2-((4s)-6-(4-클로로페닐)-1-메틸-4h-벤조[c]이속사졸로[4,5-e]아제핀-4-일)아세트아미드 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CA3218297A1 (en) | 2021-05-11 | 2022-11-17 | Gozde Colak | Use of pelabresib for treating anemias |
| KR102619332B1 (ko) * | 2021-11-30 | 2024-01-02 | 주식회사 베노바이오 | Bet 단백질을 저해하는 신규한 카르복스아마이드 리독스 유도체 및 이를 이용한 안과질환 예방 및 치료용 조성물 |
| EP4472981A1 (en) | 2022-01-31 | 2024-12-11 | Constellation Pharmaceuticals, Inc. | Anhydrous crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
| CN119365455A (zh) | 2022-04-19 | 2025-01-24 | 纽韦卢森公司 | 对溴结构域有活性的化合物 |
| JP2025542349A (ja) | 2022-12-20 | 2025-12-25 | コンステレーション・ファーマシューティカルズ・インコーポレイテッド | 比較的低リスクの骨髄異形成症候群を治療する方法 |
| WO2025067451A1 (zh) * | 2023-09-27 | 2025-04-03 | 北京沐华生物科技有限责任公司 | 一类brd4蛋白降解剂化合物及其制备方法和应用 |
| WO2025137396A1 (en) * | 2023-12-20 | 2025-06-26 | Constellation Pharmaceuticals, Inc. | Synthesis of bromodomain inhibitors |
Family Cites Families (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3523939A (en) | 1967-07-03 | 1970-08-11 | Hoffmann La Roche | 5-(2,6-disubstituted phenyl)-1,4-benzodiazepines and methods for their preparation |
| CH498846A (de) | 1967-08-09 | 1970-11-15 | Hoffmann La Roche | Verfahren zur Herstellung von Benzodiazepin-Derivaten |
| US3709898A (en) | 1971-02-09 | 1973-01-09 | Upjohn Co | Process for the production of triazolobenzodiazepines and intermediates |
| US3781289A (en) | 1971-02-09 | 1973-12-25 | Upjohn Co | 7-chloro-1-methyl-5-phenyl-s-triazolo (4,3-a)quinolines |
| US3681343A (en) | 1971-05-11 | 1972-08-01 | Upjohn Co | 6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines |
| US3903103A (en) | 1971-09-15 | 1975-09-02 | Upjohn Co | 4-Amino-s-triazolo-{8 4,3-a{9 {8 1,4{9 benzodiazepine |
| DE2242918A1 (de) | 1971-09-15 | 1973-03-22 | Upjohn Co | Neue 4-amino-s-triazolo eckige klammer auf 4,3-a eckige klammer zu eckige klammer auf 1,4 eckige klammer zu benzodiazepine |
| US3886141A (en) | 1971-10-07 | 1975-05-27 | Hoffmann La Roche | Preparation of 5-pyridyl benzodiazepine utilizing hexamethylenetetramine |
| BE795790A (fr) | 1972-02-22 | 1973-08-22 | Upjohn Co | Dibenzo-triazolo-azepine |
| US4155904A (en) | 1973-02-08 | 1979-05-22 | Schering Corporation | Process for the preparation of 1,4-benzo-diazepines and 1,4-benzodiazepinones |
| IE38931B1 (en) | 1973-03-09 | 1978-07-05 | Lipha | Triazolobenzodiazepines |
| FR2220257A1 (en) | 1973-03-09 | 1974-10-04 | Lipha | 5,6-Dihydro-(4H)-s-triazolo-(4,3-a) (1,5)benzodiazepines - as antiinflam-matory and analgesic agents without tranquillising effects |
| US3966736A (en) | 1975-04-07 | 1976-06-29 | The Upjohn Company | 2,9-Dihydro-3H-pyrido[3,2-c]-s-triazolo[4,3-a][1,5]-benzodiazepin-3-ones |
| AT350056B (de) | 1975-11-04 | 1979-05-10 | Degussa | Verfahren zur herstellung von neuen pyrido- (2,3-f)-(1,4)-diazepinen, deren optischen isomeren und salzen |
| DE2640599A1 (de) | 1976-09-09 | 1978-03-16 | Scherico Ltd | Verfahren zur herstellung von 1,4- benzodiazepinen |
| CA1152066A (en) | 1980-02-08 | 1983-08-16 | Hoffmann-La Roche Limited | Benzodiazepine derivatives |
| CA1163266A (en) | 1980-07-31 | 1984-03-06 | Albert E. Fischli | Benzodiazepine derivatives |
| CA1157855A (en) | 1980-07-31 | 1983-11-29 | Albert E. Fischli | Benzodiazepine derivatives |
| US4455307A (en) | 1982-01-04 | 1984-06-19 | The Upjohn Company | Antihypertensive use of triazolobenzodiazepines |
| US5004741A (en) | 1984-06-26 | 1991-04-02 | Merck & Co., Inc. | Methods of antagonizing CCK or gastrin with benzodiazepine analogs |
| US4820834A (en) | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
| US4663321A (en) | 1984-06-26 | 1987-05-05 | Merck & Co., Inc. | Triazolobenzodiazepines and pharmaceutical use |
| EP0315698B1 (en) | 1987-05-28 | 1993-03-03 | Yoshitomi Pharmaceutical Industries, Ltd. | Thieno(triazolo)diazepine compounds and medicinal application of the same |
| MC1999A1 (fr) | 1987-12-18 | 1990-01-26 | Hoffmann La Roche | Composes tricycliques |
| US4959361A (en) | 1987-12-18 | 1990-09-25 | Hoffmann-La Roche Inc. | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists |
| EP0348523A4 (en) | 1987-12-22 | 1991-10-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compounds and their medicinal use |
| CA1324863C (en) | 1988-01-30 | 1993-11-30 | Welfide Corporation | Thienotriazolodiazepine compounds and pharmaceutical uses thereof |
| CA1322367C (en) | 1988-05-17 | 1993-09-21 | Yoshitomi Pharmaceutical Industries Ltd. | Thienotriazolodiazepine compounds and pharmaceutical uses thereof |
| FI95708C (fi) | 1988-10-31 | 1996-03-11 | Eisai Co Ltd | Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi |
| US5382579A (en) | 1988-10-31 | 1995-01-17 | Eisai Co., Ltd. | Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals |
| US5221671A (en) | 1988-10-31 | 1993-06-22 | Eisai Co., Ltd. | Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals |
| DE3936828A1 (de) | 1988-11-06 | 1990-05-10 | Boehringer Ingelheim Kg | Neue hetrazepine |
| DE4006471A1 (de) | 1989-03-03 | 1990-09-06 | Boehringer Ingelheim Kg | Neue thienodiazepine |
| EP0407955A1 (de) | 1989-07-12 | 1991-01-16 | Boehringer Ingelheim Kg | Neue Hetrazepine mit PAF-antagonistischer Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP0411668B2 (en) | 1989-08-04 | 1998-11-11 | MERCK SHARP & DOHME LTD. | Central cholecystokinin antagonists for treatment of psychiatric disorders |
| US5175159A (en) | 1989-10-05 | 1992-12-29 | Merck & Co., Inc. | 3-substituted-1,4-benzodiazepines as oxytocin antagonists |
| IL96613A0 (en) | 1989-12-18 | 1991-09-16 | Merck & Co Inc | Pharmaceutical compositions containing benzodiazepine analogs |
| IE904560A1 (en) | 1989-12-18 | 1991-06-19 | Merck & Co Inc | New benzodiazepine analogs |
| WO1994006801A1 (fr) | 1990-05-23 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation comme medicament |
| JP2959591B2 (ja) | 1990-05-23 | 1999-10-06 | 吉富製薬株式会社 | チエノトリアゾロジアゼピン化合物 |
| DE4027470A1 (de) | 1990-08-30 | 1992-03-05 | Boehringer Ingelheim Kg | Neue hetrazepinoide amide |
| JP2959598B2 (ja) | 1990-10-12 | 1999-10-06 | 吉富製薬株式会社 | 光学活性なチエノトリアゾロジアゼピン化合物 |
| US5206234A (en) | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
| CA2056809A1 (en) | 1990-12-07 | 1992-06-08 | Mark G. Bock | Benzodiazepine analogs |
| DE4101146A1 (de) | 1991-01-16 | 1992-07-23 | Boehringer Ingelheim Kg | Neue in 6-position substituierte diazepine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| DE4107521A1 (de) | 1991-03-08 | 1992-09-10 | Boehringer Ingelheim Kg | Neue acylaminosubstituierte hetrazepine |
| US5683998A (en) | 1991-04-23 | 1997-11-04 | Toray Industries, Inc. | Tricyclic triazolo derivatives, processes for producing the same and the uses of the same |
| US5185331A (en) | 1991-05-14 | 1993-02-09 | Merck & Co., Inc. | Triazolobenzodiazepines |
| CA2071092A1 (en) | 1991-06-14 | 1992-12-15 | Roger M. Freidinger | 1,4-benzodiazepines with 5-membered heterocyclic rings |
| GB9117852D0 (en) | 1991-08-19 | 1991-10-09 | Merck Sharp & Dohme | Therapeutic agents |
| US5153191A (en) | 1991-08-20 | 1992-10-06 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
| DE4128581A1 (de) | 1991-08-28 | 1993-03-04 | Boehringer Ingelheim Kg | Verwendung von paf-antagonisten hetrazepinoider struktur zur behandlung der allergischen rhinitis |
| ES2140396T3 (es) | 1991-09-30 | 2000-03-01 | Yoshitomi Pharmaceutical | Compuesto de tienodiazepina y su uso. |
| US5593988A (en) | 1991-10-11 | 1997-01-14 | Yoshitomi Pharmaceutical Industries, Ltd. | Therapeutic agent for osteoporosis and diazepine compound |
| ES2143993T3 (es) | 1991-12-11 | 2000-06-01 | Yoshitomi Pharmaceutical | Farmaco para tratar una enfermedad autoinmune. |
| JPH07507993A (ja) | 1991-12-20 | 1995-09-07 | メルク シヤープ エンド ドーム リミテツド | 医薬活性を有する中枢神経系コレシストキニンアンタゴニスト |
| DE4200610A1 (de) | 1992-01-13 | 1993-07-15 | Boehringer Ingelheim Kg | Verwendung von paf-antagonisten zur behandlung der dysmenorrhea |
| JPH07505155A (ja) | 1992-03-24 | 1995-06-08 | メルク シヤープ エンド ドーム リミテツド | コレシストキニン及び／又はガストリン拮抗活性を有する３−ウレイド置換ベンゾジアゼピン−２−オン及び治療におけるその使用 |
| DE4219659A1 (de) | 1992-06-16 | 1993-12-23 | Boehringer Ingelheim Kg | Die Verwendung von PAF-Antagonisten in Kombination mit Anticholinergika |
| EP0661284A1 (en) | 1992-09-18 | 1995-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
| JP3223290B2 (ja) | 1992-11-10 | 2001-10-29 | 日本電信電話株式会社 | マイクロ回転体およびその製造方法 |
| US5302590A (en) | 1992-12-18 | 1994-04-12 | Hoffmann-La Roche Inc. | Compounds useful as dual antagonists of platelet activating factor and leukotriene D4 |
| WO1994022872A1 (fr) | 1993-03-30 | 1994-10-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Inhibiteur d'adhesion cellulaire et compose a base de thienotriazolodiazepine |
| EP0698015A1 (en) | 1993-05-14 | 1996-02-28 | Genentech, Inc. | Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole |
| US5760031A (en) | 1993-07-29 | 1998-06-02 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5516774A (en) | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| US5869483A (en) | 1993-07-29 | 1999-02-09 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5733905A (en) | 1993-07-29 | 1998-03-31 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| JP2840454B2 (ja) | 1993-11-22 | 1998-12-24 | メルク エンド カンパニー インコーポレーテッド | ベンゾジアゼピン類 |
| EP0686636B1 (en) | 1993-12-28 | 2001-04-04 | Meiji Seika Kabushiki Kaisha | Tricyclic benzazepine and benzothiazepine derivatives |
| US5739129A (en) | 1994-04-14 | 1998-04-14 | Glaxo Wellcome Inc. | CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines |
| US5795887A (en) | 1994-04-15 | 1998-08-18 | Glaxo Wellcome Inc. | Method of inducing cholecystokinin agonist activity using 1,4- Benzodiazepine compounds |
| WO1997011061A1 (en) | 1995-09-21 | 1997-03-27 | Nikken Chemicals Co., Ltd. | Compounds potentiating retinoid |
| CN1227555A (zh) | 1996-06-12 | 1999-09-01 | 日本烟草产业株式会社 | 细胞因子生成抑制剂、三氮䓬化合物及其中间体 |
| PT989131E (pt) * | 1996-09-13 | 2003-03-31 | Mitsubishi Pharma Corp | Compostos de trienotriazolodiazepina e suas utilizacoes com fins medicinais |
| HRP970705A2 (en) | 1996-12-23 | 1998-10-31 | Warren J. Porter | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS |
| CA2294139A1 (en) | 1997-06-25 | 1998-12-30 | Nikken Chemicals Co., Ltd. | Triazolo-1,4-diazepine compounds and medicinal composition containing the same |
| JP4204657B2 (ja) | 1997-12-05 | 2009-01-07 | 有限会社ケムフィズ | 糖尿病の予防・治療剤 |
| JPH11228576A (ja) | 1997-12-10 | 1999-08-24 | Japan Tobacco Inc | アポトーシス抑制剤 |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| PE20000944A1 (es) | 1998-07-31 | 2000-09-20 | Lilly Co Eli | Derivados de sulfonamida |
| WO2000012547A2 (en) | 1998-09-01 | 2000-03-09 | Innogenetics N.V. | Benzodiazepines and benzothiazepines derivatives and hbsag peptides binding to annexins, their compositions and use |
| US6277844B1 (en) * | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| WO2000054778A1 (fr) | 1999-03-12 | 2000-09-21 | Welfide Corporation | Agents preventifs ou therapeutiques des dermatoses inflammatoires |
| FR2791980B1 (fr) | 1999-04-09 | 2001-07-06 | Sod Conseils Rech Applic | Pyrido-thieno-diazepines, leur procede de preparation, et les compositions pharmaceutiques les contenant |
| US7160880B1 (en) | 1999-05-14 | 2007-01-09 | Cenes Limited | Short-acting benzodiazepines |
| GB9911152D0 (en) | 1999-05-14 | 1999-07-14 | Glaxo Group Ltd | Short-acting benzodiazepines |
| WO2001047510A2 (en) | 1999-12-29 | 2001-07-05 | Glaxo Group Limited | Methods and compositions related to modulators of annexin and cartilage homeostasis |
| CA2412776C (en) | 2000-06-16 | 2011-03-15 | Mitsubishi Pharma Corporation | Compositions controlling release ph range and/or speed |
| IL159105A0 (en) | 2001-06-07 | 2004-05-12 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof |
| EP1481977A4 (en) | 2002-03-01 | 2006-02-01 | Astellas Pharma Inc | NITROGENIC HETEROCYCLIC COMPOUND |
| US20060128695A1 (en) | 2002-10-30 | 2006-06-15 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| ATE473980T1 (de) | 2002-12-18 | 2010-07-15 | Vertex Pharma | Triazolopyridazine als proteinkinase-inhibitoren |
| US7119088B2 (en) | 2003-02-19 | 2006-10-10 | Pfizer Inc. | Triazole compounds useful in therapy |
| JPWO2005002590A1 (ja) | 2003-07-01 | 2006-08-10 | アステラス製薬株式会社 | 骨量増加誘導剤 |
| WO2005099759A1 (ja) | 2004-04-16 | 2005-10-27 | Institute Of Medicinal Molecular Design. Inc. | 動脈硬化症の予防及び／又は治療のための医薬 |
| JP4494414B2 (ja) | 2004-10-05 | 2010-06-30 | パイオニア株式会社 | オーディオラック |
| EP1887008B1 (en) | 2005-05-30 | 2021-04-21 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compound and a medicinal use thereof |
| JP2009502929A (ja) | 2005-07-29 | 2009-01-29 | メルク エンド カムパニー インコーポレーテッド | ヘテロ環式ベンゾジアゼピンｃｇｒｐ受容体アンタゴニスト |
| US20070105844A1 (en) | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
| AU2006306347A1 (en) | 2005-10-26 | 2007-05-03 | The Regents Of The University Of Michigan | Therapeutic compositions and methods |
| DE102005061840A1 (de) | 2005-12-23 | 2007-06-28 | Merck Patent Gmbh | Triazolderivate |
| KR20090055001A (ko) | 2006-08-25 | 2009-06-01 | 닛뽕 케미파 가부시키가이샤 | Ｐ2ｘ4 수용체 길항제 |
| WO2008109856A2 (en) | 2007-03-07 | 2008-09-12 | Xenon Pharmaceuticals Inc. | Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions |
| US20090111780A1 (en) | 2007-10-31 | 2009-04-30 | Everett Laboratories, Inc. | Compositions and methods for treatment of ear canal infection and inflammation |
| ITFI20070288A1 (it) | 2007-12-21 | 2009-06-22 | A I L Firenze Sezione Autonoma | Inibitori delle deacetilasi istoniche |
| EP2239264A4 (en) | 2007-12-28 | 2012-01-11 | Mitsubishi Tanabe Pharma Corp | ANTITUMORAL MEDIUM |
| CN102123706B (zh) | 2008-06-17 | 2013-08-14 | 米纳斯吉拉斯联合大学 | 血小板活化因子受体在治疗黄病毒科病毒引起的感染中的用途 |
| MX2011000021A (es) | 2008-06-23 | 2011-02-24 | Vertex Pharma | Inhibidores de proteina cinasas. |
| CA2741934C (en) | 2008-10-30 | 2016-09-13 | Circomed Llc | Thienotriazolodiazepine derivatives active on apo a |
| WO2010121164A2 (en) | 2009-04-17 | 2010-10-21 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
| WO2010128685A1 (en) | 2009-05-07 | 2010-11-11 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
| WO2011037128A1 (ja) | 2009-09-28 | 2011-03-31 | 日本曹達株式会社 | 含窒素ヘテロ環化合物およびその塩ならびに農園芸用殺菌剤 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| MY160456A (en) | 2009-11-05 | 2017-03-15 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| KR20120097508A (ko) | 2009-11-05 | 2012-09-04 | 글락소스미스클라인 엘엘씨 | 벤조디아제핀 브로모도메인 억제제 |
| WO2011054851A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Novel process |
| EP2515914A4 (en) | 2009-12-23 | 2013-09-11 | Scripps Research Inst | BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA |
| TW201201813A (en) | 2010-03-31 | 2012-01-16 | Arqule Inc | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US8981083B2 (en) | 2010-05-14 | 2015-03-17 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
| CA2799381A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
| JP5913292B2 (ja) | 2010-05-14 | 2016-04-27 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 代謝を調節する組成物および方法 |
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| US9085582B2 (en) | 2010-06-22 | 2015-07-21 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| WO2013033420A1 (en) | 2011-08-30 | 2013-03-07 | Whitehead Institute For Biomedical Research | Methods of downregulating translocated oncogene expression using bromodomain inhibitors |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| TWI602820B (zh) * | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
-
2011
- 2011-12-01 AR ARP110104481 patent/AR084070A1/es active IP Right Grant
- 2011-12-02 JP JP2013542202A patent/JP5850944B2/ja active Active
- 2011-12-02 US US13/309,646 patent/US8796261B2/en active Active
- 2011-12-02 AU AU2011336417A patent/AU2011336417B2/en active Active
- 2011-12-02 NZ NZ611964A patent/NZ611964A/en unknown
- 2011-12-02 WO PCT/US2011/063046 patent/WO2012075383A2/en not_active Ceased
- 2011-12-02 HR HRP20150858TT patent/HRP20150858T1/hr unknown
- 2011-12-02 SI SI201130558T patent/SI2646446T1/sl unknown
- 2011-12-02 CA CA2818187A patent/CA2818187C/en active Active
- 2011-12-02 KR KR1020137017209A patent/KR101871013B1/ko active Active
- 2011-12-02 PT PT118445139T patent/PT2646446E/pt unknown
- 2011-12-02 BR BR112013013167-5A patent/BR112013013167B1/pt active IP Right Grant
- 2011-12-02 ES ES11844513.9T patent/ES2545117T3/es active Active
- 2011-12-02 CN CN201180065291.7A patent/CN103415525B/zh active Active
- 2011-12-02 HU HUE11844513A patent/HUE025321T2/en unknown
- 2011-12-02 RS RS20150536A patent/RS54175B1/sr unknown
- 2011-12-02 EA EA201390803A patent/EA022645B1/ru unknown
- 2011-12-02 TW TW100144346A patent/TWI572607B/zh active
- 2011-12-02 DK DK11844513.9T patent/DK2646446T3/en active
- 2011-12-02 MX MX2013006214A patent/MX2013006214A/es unknown
- 2011-12-02 EP EP11844513.9A patent/EP2646446B1/en active Active
- 2011-12-02 SG SG2013042064A patent/SG190739A1/en unknown
- 2011-12-02 PL PL11844513T patent/PL2646446T3/pl unknown
-
2013
- 2013-05-13 IL IL226331A patent/IL226331A/en active IP Right Grant
- 2013-05-23 ZA ZA2013/03776A patent/ZA201303776B/en unknown
-
2014
- 2014-06-24 US US14/313,148 patent/US9522920B2/en active Active
-
2015
- 2015-08-06 CY CY20151100688T patent/CY1116578T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544847A5 (enExample) | ||
| HRP20150858T1 (hr) | Inhibitori bromodomena i njihove uporabe | |
| JP2018516994A5 (enExample) | ||
| US12391663B2 (en) | Isoindolinone compounds | |
| ES2930305T3 (es) | Inhibidores del bromodominio | |
| CN110573500A (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| CN107108631B (zh) | 作为蛋白激酶抑制剂的6-氨基-7-二环-7-脱氮-嘌呤衍生物 | |
| JP2015518899A5 (enExample) | ||
| CN106536509B (zh) | 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物 | |
| ES2742409T3 (es) | Inhibidores de quinasa de pirazolilquinoxalina | |
| ES2968809T3 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| RU2707953C2 (ru) | Производное пиридона, имеющее тетрагидропиранилметильную группу | |
| CN115803325A (zh) | 一种egfr抑制剂及其制备方法和应用 | |
| HRP20230466T1 (hr) | Kristalni čvrsti oblici bet inhibitora | |
| JP2019524660A5 (enExample) | ||
| TW200526650A (en) | Isoquinoline derivatives | |
| JP2015518894A5 (enExample) | ||
| JP2013534245A5 (enExample) | ||
| JP2016523973A5 (enExample) | ||
| JP2019516766A5 (enExample) | ||
| JP2011513331A (ja) | ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤 | |
| CN102858754A (zh) | Raf抑制剂化合物及其使用方法 | |
| JP2013503190A (ja) | Ｒａｆ阻害化合物およびその使用方法 | |
| WO2013170770A1 (zh) | 具有抗肿瘤活性的乙炔衍生物 | |
| JP2017537114A5 (enExample) |